Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.

@article{King2000ComparisonOT,
  title={Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.},
  author={J. R. C. King and John T Treanor and Patricia E. Fast and Mark Wolff and Lihan K Yan and Dominick A Iacuzio and Bernard X Readmond and Diane M O'brien and Kerry Mallon and W. Edward Highsmith and J. Si{\^a}n Lambert and Robert B. Belshe},
  journal={The Journal of infectious diseases},
  year={2000},
  volume={181 2},
  pages={
          725-8
        }
}
Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1-2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients… CONTINUE READING
Tweets
This paper has been referenced on Twitter 5 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 citations